MedTrace Logo

The Combination of IVIG, Dexamethasone and a Megadose of PBSCs for Decreasing DSAs

NCT06471478 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2024-06-24

No results posted yet for this study

Summary

Donor-specific antibodies (DSAs) are essential causes of graft rejection in haploidentical hematopoietic stem cell transplantation (haplo-HSCT). DSAs are unavoidable for some patients who have no alternative donor. Effective interventions to reduce DSAs are still needed, and the cost of the current therapies is relatively high. Investigators wanted to retrospectively analyzed the data of 11 DSA-positive participants who received haplo-HSCT at our center and evaluated the therapeutic efficacy of the combination of intravenous immunoglobulin (IVIG), dexamethasone and megadose of transfused peripheral blood stem cells (PBSCs) for DSA desensitization.

Conditions

  • Blood Disease

Interventions

COMBINATION_PRODUCT

intravenous immunoglobulin, dexamethasone and a megadose of peripheral-blood stem cell transfusion

patients received intravenous immunoglobulin, dexamethasone and a megadose of peripheral-blood stem cell transfusion for decresing donor specific antibodies.

Sponsors & Collaborators

  • Hematology department of the 920th hospital

    lead OTHER

Principal Investigators

  • Sanbin Wang, Professor · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

Eligibility

Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2021-10-30
Completion
2023-08-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06471478 on ClinicalTrials.gov